The United Kingdom (UK) will have a general election on Thursday, 12 December. The UK BioIndustry Association (BIA) has launched a biotech manifesto with its recommendations on how political parties can support the innovative UK life sciences sector.
Brainomix has been selected by Boehringer Ingelheim, the leading biopharmaceutical company providing therapeutic options for interstitial lung disease (ILD).
J.P. Morgan’s healthcare conference may be wrapped up, but it has set some tangible momentum and without doubt a more buoyant mood for global life sciences going into 2026.
An acknowledgment from Astrea Bioseparations celebrating LIB Therapeutics' achievement of FDA approval for LEROCHOL™, including some collaboration efforts.
As we settle into the rhythms of daily life and gather our thoughts about the year ahead, our policy experts have weighed in on what the life sciences sector might expect in 2026.
